Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates.
Surgeons have constantly sought to achieve the most aesthetic scar. A major factor determining the final cosmetic appearance of a cutaneous scar is the tension acting on the wound edges during the healing phase. Since Theodor Kocher pioneered the alignment of skin incisions with Langer's lines in 1892, surgical techniques that attempt to overcome closing tension have become standard. Yet, no treatment has been available to minimize underlying muscle contractions, which are the major cause of this tension. Botulinum toxin A is a potent drug that produces temporary muscular paralysis when injected locally. It has proven to be safe and effective in the treatment of a variety of disorders, including hyperkinetic facial lines. The objective of this randomized, double-blind, placebo-controlled primate study was to investigate the efficacy of a single injection of botulinum toxin A to improve the cosmetic appearance of cutaneous scars. Symmetric pairs of standardized excisions were performed on either side of the forehead of six primates. The half foreheads were randomized to the botulinum toxin A treatment side versus the placebo injection side. A panel of three blinded facial surgeons assessed the cosmetic appearance of the mature scars 3 months postoperatively. The wounds that had been immobilized with botulinum toxin A were rated as significantly better in appearance than the control wounds (p < 0.01). Histologic examination confirmed that all scars were mature. Blinded, randomized, placebo-controlled human clinical trials are presently under way at the Mayo Clinic.
Gassner
H G
HG
Department of Otorhinolaryngology at the Mayo Clinic, Rochester, Minn 55905, USA.
Sherris
D A
DA
Otley
C C
CC
D000818:Animals; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002921:Cicatrix / Q000473:pathology / Q000517:prevention & control; D004954:Esthetics; D005151:Facial Injuries / Q000473:pathology / Q000628:therapy*; D008252:Macaca fascicularis; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D011897:Random Allocation; D012867:Skin / Q000473:pathology; D014945:Wound Healing
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A